Corpus overview


Overview

MeSH Disease

Human Phenotype

Pneumonia (3)


Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    Breast Milk-fed Infant of COVID-19 Pneumonia Mother: a Case Report

    Authors: Yuanyuan Yu; Jian Xu; Youjiang Li; Yingying Hu; Bin Li

    doi:10.21203/rs.3.rs-20792/v1 Date: 2020-04-01 Source: ResearchSquare

    In China, mothers with confirmed or suspected COVID-19 pneumonia HP pneumonia MESHD are recommended to stop breastfeeding. However, the evidence to support this guidance is lacking. This report analyzes the case of a mother who persisted breastfeeding her baby when both were diagnosed with confirmed COVID-19 pneumonia HP pneumonia MESHD. SARS-CoV-2 nucleic acid was not detected in the breast milk MESHD, and antibodies SERO against SARS-CoV-2 were present in detected in the mother's serum SERO and milk. There was no evidence of mother-to- child TRANS transmission TRANS of the virus through breastfeeding. This case report demonstrates that breastfeeding may even be useful for improving the recovery of the infant without exacerbating disease severity.

    Rapid development of a synthetic DNA vaccine for COVID-19

    Authors: Trevor R.F. Smith; Ami Patel; Stephanie Ramos; Dustin Elwood; Xizhou Zhu; Jian Yan; Maria Yang; Neethu Chokkalingam; Ebony N. Gary; Katherine Schultheis; Patrick Pezzoli; Jewell Walters; Susanne N. Walker; Elizabeth Parzych; Emma L. Reuschel; Arthur Doan; Nicholas Tursi; Miguel Vasquez; Jihae Choi; Igor Maricic; Mamadou A. Bah; Yuanhan Wu; Dinah Amante; Daniel Park; Yaya Dia; Ali Raza Ali; Faraz I. Zaidi; Alison Generotti; Kevin Y. Kim; Timothy A. Herring; Sophia Reeder; Ami Shah Brown; Makan Khoshnejad; Nianshuang Wang; Jacqueline Chu; Daniel Wrapp; Jason S McLellan; Kar Muthumani; J Joseph Kim; Jean Boyer; Daniel W. Kulp; Laurent M.P.F. Humeau; David B. Weiner; Kate E. Broderick

    doi:10.21203/rs.3.rs-16261/v1 Date: 2020-03-03 Source: ResearchSquare

    The coronavirus family member TRANS, SARS-CoV-2 has been identified as the causal agent for the outbreak of viral pneumonia disease MESHD pneumonia HP disease, COVID-19 which first emerged in mid-December 2019 in the city of Wuhan in central China. As of February 25, 2020 there are 80,994 people infected MESHD and 2,760 deaths, and documented human-to-human transmission TRANS across multiple continents. At this time, no vaccine is available to control further dissemination of the disease. We have previously developed a synthetic DNA vaccine targeting the MERS coronavirus Spike MESHD (S) protein that was deployed in response to the MERS outbreak in South Korea. This vaccine induced potent antibody SERO and CTL responses, and provided protection in a NHP challenge model. In the clinic, the vaccine generated humoral immunity including neutralizing antibody SERO responses, as well as T cell immunity. Here we build on this prior work and report on the rapid development of a synthetic DNA-based vaccine targeting the major surface antigen Spike protein of SARS-CoV-2. The engineered construct, INO-4800 induced robust expression of the Spike protein in vitro, and generated antibody SERO and T cell responses following a single immunization in mice and guinea pigs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further study for mobilization against this emerging disease threat. 

    Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening

    Authors: Yan Li; Jinyong Zhang; Ning Wang; Haibo Li; Yun Shi; Gang Guo; Kaiyun Liu; Hao Zeng; Quanming Zou

    doi:10.1101/2020.01.28.922922 Date: 2020-01-29 Source: bioRxiv

    2019 Novel Coronavirus (2019-nCoV) is a virus identified as the cause of the outbreak of pneumonia HP pneumonia MESHD first detected in Wuhan, China. Investigations on the transmissibility TRANS, severity, and other features associated with this virus are ongoing. Currently, there is no vaccine or therapeutic antibody SERO to prevent the infection MESHD, and more time is required to develop an effective immune strategy against the pathogen. In contrast, specific inhibitors targeting the key protease involved in replication and proliferation of the virus are the most effective means to alleviate the epidemic. The main protease of SARS-CoV MESHD is essential for the life cycle of the virus, which showed 96.1% of similarity with the main proteaseof 2019-nCoV, is considered to be an attractive target for drug development. In this study, we have identified 4 small molecular drugs with high binding capacity with SARS-CoV MESHD main protease by high-throughput screening based on the 8,000 clinical drug libraries, all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection MESHD of 2019-nCoV.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.